Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.

Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.

Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.

Abstract: A book-like packaging structure for receiving at least one blister pack having at least one receptacle. The book-like packaging structure includes at least one inner blister pack retainer for receiving the at least one blister pack, the at least one inner blister pack retainer having an inner edge, an outer edge, a first retainer portion and a second retainer portion, said second retainer portion adjacent an inner spine panel having a width equal to or greater than the depth of the at least one receptacle; and a cover for enclosing the at least one inner blister pack retainer, the cover having a first cover portion having an inner edge, a second cover portion having an inner edge and a spine, the spine joined to the inner edge of the first cover portion and the inner edge of the second cover portion, wherein the inner spine panel rests against the spine such that the inner edge of the at least one inner blister pack retainer is positioned adjacent to the spine of the cover.

Abstract: A book-like packaging structure for receiving at least one blister pack having at least one receptacle. The book-like packaging structure includes at least one inner blister pack retainer for receiving the at least one blister pack, the at least one inner blister pack retainer having an inner edge, an outer edge, a first retainer portion and a second retainer portion, said second retainer portion adjacent an inner spine panel having a width equal to or greater than the depth of the at least one receptacle; and a cover for enclosing the at least one inner blister pack retainer, the cover having a first cover portion having an inner edge, a second cover portion having an inner edge and a spine, the spine joined to the inner edge of the first cover portion and the inner edge of the second cover portion, wherein the inner spine panel rests against the spine such that the inner edge of the at least one inner blister pack retainer is positioned adjacent to the spine of the cover.